JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Tuberculosis In HIV-Infected Patients

Mr. Rajesh Kuma, Dr. Tun Veer Singh Arya, * Dr. Amar Prakash Garg
Medical College and Hospital, Meerut,(UP),India;
*Shobhit Deemed University, Meerut,(UP),India;

ABSTRACT

The incident ceoftuberculosis (TB) is currently increasing in HIV-infected patients living in India and Southern India, where TB endemic city is high, reflecting this us acceptability of this group of patients to mycobacteria belonging to the TB group. In this population, extension on of multiple resistance to anti-tuberculous drugs is also a matter of anxiety. HIV-induced immune suppression on modifies the clinical presentation of TB, resulting in a typical signs and symptoms, and more frequent extra pulmonary dissemination. The treatment of TB is also more difficult to manage in HIV-infected patients, particularly with regard to pharmacologic AL interaction s secondary to inhibition or induction of cytochrome P450 enzymes by protease inhibitors with rife picnic or hifalutin, respectively. The World Health Organization recommends in stetting immediate therapy for MTB, in conjunction with ongoing or newly introducedanti –retro viral therapy. Vigilance is required to detect drug- induced organ injuries, and early-treatment-induced immunize constitution inflammation or syndrome. Collaborating MTB and HIV activities in concentrated HIV epidemic settings hold become a high public he al the priority.

Keywords: AIDS, HAART, HIV, Mycobacterium, tuberculosis

INTRODUCTION

Air born Trans mission of Mycobacterium tuberculosis is responsible for primary tuberculosis (TB) infection which can evolveinimm udo competent, but more frequently in immune compromised hosts into TB. The number of TB cases as increased dramatically worldwide, reflecting this us acceptability of HIV-infected patients to the M. tuberculous is complex. Because of this, pulmonary TB was considered in the 1993 Centers for Disease Control classification of AIDS Asatru AIDS-defining illness in HIV infected patients, similar to Pneumocystis cariniipneumonia, cerebral too plasmosisor extra-pulmonary system mycoses. However, in contrast to most of these other AIDS classifying opportune is tic infections, TB may occur relatively early in the course of HIV infection. Its hold be noted that there is mutual interaction between Tuberculosis and HIV. Indeed, the immune suppression in diced by HIV modifies the clinical presentation of TB and its management, while immune rest or ationinduced by h highly activate-retro viral therapy (HAART) may be associated with paradoxical main gestations related to immunize constitution. On the other hand, TB influences the prognosis of HIV infection, and anti-tuberculous drugs in termer with anti-retroviral drugs, including protease inhibitors and non-nucleons ide reverse-transcriptase inhibitors (NNRTIs). Different populations pose group-specific challenges in

response to detection and treatment. These populations include pediatric patients, antenatal HIV-infected patients, truckers, female sex workers, and men who have sex with men, refugees, and displaced populations. Other challenges exist in overcrowded settings such as mines, prisons, homeless shelters, and opioid substitution he rap centers. Social issues, including poverty, are war pied into the fabric of clinical course of HIV– M TB coinfection. In this review, we emphasize early detection by effective implementation of provide reinitiated HIV testing and counseling inTB patients as well as intent sifted TB case finding among PLHIV and initiation of prompt treatment to minimize morbidity and mortality.

PATHOPHYSIOLOGY

TB results from infection by pathogen belonging to the M.tuberculos is complex, primarily M.tuberculosis (Koch's bacillus), and rarely Mycobacterium Bo visor Mycobacterium Africanism. After penetration in to the respiratory react, these bacilli infect macrophages, while CD4+T-lymphocytes and tγδ-lymphocytes produce inter felon gamma (IFN-γ), interleukin-2 , tumournecros is factor alpha (TNFα), and macrophage colony- stimulating factor, which activate macrophages and cytotoxic cells to inhibit their intracellular growth. TB appears when the immune response inducing granule mails insufficient to limit the growth of mycobacteria. IFN-γ plays a pivotal role at this stage. Indeed, people her pouring genetic defects that result in reduced production of either IFN-orbits cellular recap to redevelops ever and fatal TB. During HIV infection, IFN-γ production is decreased dramatically in parallel with the reduction ofCD4+T-lymphocytes, which leads finally to a markedly increased risk of developing reactivation or reinfection by M.tuberculosis in these patients. Conversely, TB may also influence HIV evolution. Pro inflammatory cytokine production by tuberculous granulomas (in particular TNFα) has been as associated with increased HIV viremia, which mightaccele rate the course towards severe immune suppression. The risk of death in HIV-infected patients with TB is twice that in HIV-infected patients without TB with matched CD4 cell counts, with most deaths caused by progressive HIV infection, rather than TB.

Pathogenesis of Mycobacterium tuberculosis–HIV Coinfection

The details of immune responses to TB, HIV, and coinfections have been described in recent reviews. It is important to note that MTB occurs earlier in HIV patients h another opportune is tic in factions (OIs) due to increased susceptibility of MTB-specific CD4+ T cells to HIV infection. We present the immune pathogens is in relation to the intensity of the clinical presentation of TB with pre-existing HIV infection.

Tuberculous is infection is a result of the inter play between bacterial virus lanced host resistance. The infection be gins through in halation of air droplets containing approximately 1–200 bacilli from an individual with active MTB (pulmonary) disease. The bacilliarera paly phagocytose day resident macrophages in the alveoli. This triggers an inflammatory cascade, followed by development of granuloma. Furthermore, cell-mediated immunity through activation of CD4–Lymphocytes is important in the prevention of MTB disease's acceleration and reactivation.

On the other hand, HIV transmitted primarily through genital fluids, blood, and mucosa interacts with different cells in the body and tend seascape the host immune response against it, resultinginfull – blown AIDS disease. Progression of HIV infection is a result of a combination of CD4+ Lymphocytes depletion and chronic state of immune inactivation. The repression of CD4+Tcells and impairment to macro phages' activity in HIV/AIDS results in down-regulation of the body's immune response to infections, such as MTB. Mycobacteria are contained within granuloma as; however, the disruption leads to MTB bacterial growth and systemic disuse in action to multiple organs. MTB has a negative impact on the immune response of the body to HIV by up- regulating the immune response of the host by activating T-cells. Studies have amongst rated that MTB enhances HIV viral replication by

increasing the expression receptors (e.g., CXCR4), which favors viral growth. The immune responses responsible for the vigoro TB infection in a HIV-confected host and irresponsible formulary and extra pulmonary presentations and its associated diagnostic dilemma. Studies aiming too bat indirect evidence of disease progress on have been limited due to economy reasons of HIV viral loads taxation, especially in countries where the incidence/ prevalence of HIV–MTB coinfection is high but has the short coming of resource constraints. As pointed out, the impact of MTB on HIV disease progression primarily involves up regulated HIV-1 viral load, including the development to few OIs. Interestingly, TB was found to exert significant effect on diminishing survival rates in subjects with more preserved immunological status (i.e., CD4cellcounts>200cells/μL).

Enhanced HIV-1 production has be undemonstrated at local sites of MTB infection, for example, in Brunch oleo Lar lavage (BAL) fluid from TB involved, compared with un involved, lungs of patients with HIV-1/ TB coinfection. A clinical presentation of TB that is particularly observed in HIV-1-infected patients is pleural TB, common presentation in India confected patients. These sites of active MTB infection act as foci of HIV replication and devolution of quasi- species, independent of systemic HIV-1 activity, and may be responsible for disseminated MTB infection in HIV-1 confected hosts.

Mycobacterium tuberculosis is breaches the alveoli are epithelium during the first phase of extra pulmonary dissemination. Molecular mechanisms for this cytolysis have been reported. For example, he par in-binding he agglutinin in adhesion (HBHA) facilitates MTB to bind to sulfated glycol conjugates one epithelial cells. Two gene products of the MTB RD1gene, early secretory anti genic target 6kDa (ESAT-6) and culture fil trade protein 10 kids (CFP-10), have been causally linked to the cell lysis and extra pulmonary mycobacterial spread. The trafficking go mycobacteria to their going al lymph nodes, while essential for the development of protective T- cell-mediated immune response, is the first extra pulmonary site of migration not MTB.Bacteria there after disseminated through the blood stream and lymphatics lead to extra pulmonary tuberculosis (EPTB).
Lung granuloma as from MTB/HIV-1 confected patients release lower level so finite TNF production. Additionally, MTB–HIV-1 confected hosts have low circulating mannose-binding lectin levels. The complex interactions that take place between host T cells, Trigs, cytokine production, and over allium paired The 1 responses pried is pose to extra pulmonary infections in HIV-confected hosts. Several primary
Immune deficiencies, including Men Delian susceptibility to mycobacterial infections, enhance the overall risk of EPTB. These as pacts merit detailed studies in the future.

Complications Arising Out of Therapy for HIV–MTB Coinfection

Immune Reconstitution Inflammatory Syndrome

Transit Entex acer bastion of respiratory signs and symptoms despite reduction in viral load and/ or radiological deterioration may develop in HIV–M TB confected patients who are treated with anti-TB medications concomitantly with HAART. IRIS has dimorphic presentation: UN masking and paradoxical. Restoration of immune competence by administration of ART results in hyper immune ehostresponse toTB bacilli and/or antigens. UN masking IRIS presents with active TB so on after ART is started. Paradoxical IRIS refers to the worsening of TB symptoms after ART is initiated in patients who are receiving TB treatment. Anti-inflammatory drugs and steroids are the main stay therapy for IRIS. Discontinuation of HAART is not war ranted in most cases. Delaying initiation of ART for 2–8

weeks may reduce the incidence and severity of IRIS. However, this possible advantage of delayed ART must be weighed against the potential benefit of earlier ART in improving immune function and preventing progression of HIV disease and mortality. Importantly, immunize constitution with ART may result in UN masking LTBI (i.e., conversion of previously negative TST to a positive TST or positive IGRA for MTB-specific proteins). A positive IGRA, similar to a positive TST, is indicative of LTB Lint he absence of evidence of active TB disease. Because treatment for LTB Ibis indicated in the absence of evidence of active TB disease, this situations hold be clinically recognized, especially in high risk groups.

Anti-Tuberculosis and Anti-Retroviral Drug Interaction

Rapamycin are potent inducers of the hepatic cytochrome P (CYP) 450 enzyme. They are as associated with significantinter actions with a llPIs , some non-nucleoside reverse transcriptase inhibitors (NNRTIs), maraviroc (MVC), and raltegravir (RAL), leading to enhanced drug clear an caned significant lowering in circulating anti- retroviral drugs. However, good virological, immunological, and clinical outcomes may be achieved with standard dose so fefavirenz (EFV) and nevirapine (NVP) when combined with rifampin. Suboptimal HIV suppression or suboptimal response to TB treatments hold prompt mimed at assessment of drug adherence, sub-therapeutic drug levels (with consideration for the rape tic drug monitoring), and acquired drug resistance.

Other Known Side Effects

Hepatic toxicity potentially rises from co-administration of anti-retroviral and antimyco bacterial agents; therefore, continuous monitoring of liver function should be exercised. Symptoms of abdominal pain, jaundice, loss of appetite, fever, and nausea merit urgent clinical attention. Additionally, many of these patients may need additional treatment, for example, for drug dependence or HCV coinfection, which presents additional risk for coexisting liver diseases. Peripheral neuropathy, on the other hand, can occur with administration of INH, didanosine (ddI), orstavudine (d4T) or may be a main gestation of the native HIV infection parse. All patients receiving INH should be administered supplement alpyridoxinet or educe peripheral neuropathy. Other coexisting medical and behavioral conditions, such as to bacco smoking, alcoholism, malnutrition, and diabetes mellitus, may significantly impact disease management and outcomes.

CONCLUSIONS

The worldwide incidence of TB is increasing currently, particularly in areas of the southern hemisphere where HIV epidemics are devastating because anti-retroviral the rapes are not available. HIV-infected patients are at extremely high risk for progression from latent TB to active disease, and unusual clinical man infestations of TB should not being or edit this high-risk group. Patients receiving HAART may have significant drug–drug interactions when rifampicin is used with PIs or NNRTIs, and also risk developing every paradoxical reactions attributable to immune restoration. HIV infected patients with active TB diseases hold receive treatment support, including adherence counseling and DOT, corresponding to their needs. In conclusion, MTB and HIV coinfection remains a diagnostic and the rape tic challenge worldwide.

Conflict of Interest Statement

The authors declare that there search was conducted in the absence of any c commercial or financial relationships that could be construed as potential conflict of interest.

References

1. PawlowskiA, JanssonM, SköldM, RottenbergME, KälleniusG.Tuberculosis and HIV coinfection. PLoSPathog (2012)8(2):e1002464. doi:10.1371/journal.ppat.1002464
2. World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization (2013).
3. Montales MT, BeebeA, ChaudhuryA, PatilN. Mycobacterium tuberculosis infectionin a HIV-positive patient. Respir MedCaseRep (2015)16:160–2. doi:10.1016/j.rmcr.2015.10.006
4. EfsenAM, SchultzeA, PostF, PanteleevA, FurrerH, MillerR, etal. Major challenges inclinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. JInt AIDSSoc (2014)17 (4Suppl3):19505. doi:10.7448/IAS.17.4.19505
5. SesterM, vanLethF, BruchfeldJ, BumbaceaD, CirilloDM, DilektasliAG, etal. TBNET. Riskassessment of tuberculos is in immune compromised patients. A TBNET study. Am JRespir Crit Care Med (2014)190(10):1168–76. doi:10.1164/rccm.201405-0967OC.
6. HotezPJ. Bluemarble healthand “the bigthree diseases”: HIV/AIDS, tuberculosis, andmalaria. Microbes Infect (2015)17(8):539–41. doi:10.1016/j.micinf.2015.05.004
7. KhabbazRF, MoseleyRR, SteinerRJ, LevittAM, BellBP. Challenges of infectious diseases in the USA. Lancet (2014)384(9937):53–63. doi:10.1016/S01406736(14)60890-4
8. PatilN, MarcoA, SabaH, SamantR, Mukasa L.TBornot TB; don’t miss the obvious. JArk MedSoc (2014)111(6):112–4.
9. BerzkalnsA, BatesJ, YeW, MukasaL, FranceAM, PatilN, etal. The road to tuberculosis (Mycobacterium tuberculosis) elimination in Arkansas; are examination of risk groups. PLoSOne (2014)9(3):e90664. doi:10.1371/journal.pone.0090664
10. CorbettEL, WattCJ, WalkerN, MaherD, WilliamsBG, Raviglione MC, etal. The growing burden of tuberculosis: global trend sand interactions with the HIV epidemic. ArchIntern Med (2003)163:1009– 21. doi:10.1001/archinte.163.9.1009
11. HolmesC, HauslerH, NunnP.Areview of sex differences in the epidemiology of tuberculosis. In tJ TubercLung Dis (1998)2(2):96–104.
12. VenturiniE, TurkovaA, ChiappiniE, GalliL, de MartinoM, Thorne. Tuberculosis and HIV co-infection in children. BMC Infect Dis (2014)14(Suppl1):S5. doi:10.1186/1471-2334-14-S1-S5.
13. RicheldiL, LosiM, D’AmicoR, LuppiM, FerrariA, MussiniC, etal. Performance of tests for latent tuberculos is in different groups of immune compromised patients. Chest (2009) 136 (1) : 198–204. doi:10.1378/chest.08-2575
14. ShankarEM, VigneshR, EllegårdR, BarathanM, ChongYK, BadorMK, etal. HIV Mycobacterium tuberculos is co-infection: a‘danger-couplemodel’ of disease pathogenesis. PathogDis (2014)70(2):110–8. doi:10.1111/2049-632X.12108
15. GeldmacherC, NgwenyamaN, SchuetzA, PetrovasC, ReitherK, HeeregraveEJ, etal. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 Tcells after HIV-1infection. JExpMed (2010)207(13):2869–81. doi:10.1084/jem.20100090
16. Scaling Up of Collaborative TB/HIV Activities in Concentrated HIV Epidemic Settings. A Case Study from India. World Health Organization (2015). Available from: Cooper A. Cell mediated immune responses in tuberculosis. Annu RevImmunol (2009) 27:393–422.doi:10.1146/annurev.immunol.021908.

17. SahariaKK, Koup RA.T cells us ceptibility to HIV influences outcome of opportunistic infections. Cell (2013)155(3):505–14.doi:10.1016/j.cell.2013.09.045.
18. MoirS, ChunT, Fauci A.Pathogenic mechanisms of HIV disease. AnnuRev Pathol (2011)6:223– 48.doi:10.1146/annurev-pathol-011110-130254.
19. Otten hof fTHM Kumararatne D Casanova JL Novel human immune deficiencies reveal the essential role of type-1cytokinesin immunity o intracel lular bacteria. Immunol Today.1998;19:491-494.
20. Marchal G Pathophysiology and immunology of tuberculosis. RevMal Respir.1997;14:S19-S26.
21. Havlir DV Barnes PF Current concepts. Tuberculos is in patients with human immune deficiency virus infection. NEng lJMed. 1999;340:367-373.
22. Garrait V Cadrane lJ EsvantH etal. Tuberculos is generat esamicro environment enhancing the productive infectionoflocal lymphocytes by HIV. JImmunol. 1997;159:2824-2830.
23. WhalenCC HorsburghCR HomD LahartC SimberkoffM EllnerJ Accelerated course of human immune deficiency virus infection after tuberculosis. Am JRespir Crit Care Med.1995;151:129-135.
24. Dye C, ScheeleS, DolinP, PathaniaV, Raviglione, MC Consensus statement. Global burden of tuberculosis. Estimated incidence revalence and mortality by country. Who Global Surve illance and Monitoring Project. JAMA.1999;282:677-686.
25. SengR, GustafsonP, GomesVF, etal. Community study of there lative impact of HIV-1 and HIV-2 on intrath or acic tuberculosis. AIDS.2002;16:1059-1066.
26. Raviglione M Harries, A MsikaR, WilkinsonD, NunnP, Tuberculosis and HIV: current status in Africa. AIDS.1997;11:S115-S123.
27. WoodR, MaartensG, LombardCJ, Risk factors for developing tuberculosis in HIV-1 infected adults from communities with alowor very high incidence of tuberculosis. JAIDS.2000;23:75-8.
28. PernegerTV, SudreP, LundgrenJ, HirschelB, Does the onset of tuberculos is in AIDS predict shorter survival? Results of a cohort study in 17 Europe a countries over 13 years. AIDS in Europe Study Group. BMJ.1995;311:1468-1471.
29. CorbettEL, S teketee, RW terKuile, FO Latif, AS Kamali, A Hayes RH HIV/AIDS and the control of other infectious diseases in Africa. Lancet. 2002;359:2177-2187.
30. LucasSB, HounnouA, PeacockCm etal. The mortality and pathology of HIV infection in a West Africacity. AIDS.1993;7:1569-1579.
31. LaurentC, DelaporteE, Epidemiology of HIV infection in sub-Saharan Africa. AIDS Rev.2001;3:59-66.
32. RanaFS, HawkenMP, MwachariL, etal. Auto psy study of HIV-1-positive and HIV-1 negative adult medical patients in Nairobi, Kenya. JAIDS.2000;24:23-29.
33. Institut de Veille Sanitaire (IVS) Surve illancedela tuberculos een France. Bull Epidemiol Hebd. 1993; 19:86-87.
34. Institut de Veille Sanitaire(IVS) SurveillanceduSIDAenFrance.Situationau30septembre2001. Bull Epidemiol Hebd.2001;47:207-212.
35. GengE, KreiswirthB, DriverC, etal. Changes in the transmissi on of tuberculos is in NewYork city from 1990to1999. NEnglJMed.2002;346:1453-1458.
36. LeonardMK, LarsenN, DrechslerH, etal. Increased survival of persons with tuberculos is and human immune deficiency virus infection,1991-2000. Clin InfectDis.2002;34:1002-1007.